Actively Recruiting
Study of CM383 in Healthy Subjects
Led by Keymed Biosciences Co.Ltd · Updated on 2026-01-23
30
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.
CONDITIONS
Official Title
Study of CM383 in Healthy Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male subjects aged 18 to 54 years
- Voluntarily signed informed consent and able to follow study procedures
You will not qualify if you...
- Smoking more than 5 cigarettes per day within 3 months before screening
- Heavy drinking within 3 months before screening, positive alcohol breath test, or inability to avoid alcohol during the study
- History of drug abuse within 1 year before screening or positive drug screening
- Blood donation or blood loss over 400 mL, or blood transfusion within 12 weeks before screening
- Suspected allergy to Aβ-antibody drugs, humanized monoclonal antibodies, other biological agents, or history of severe allergic reactions
- Severe trauma or major surgery within 6 months before screening, or planned surgery during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital Zhejiang University School of Medcine
Hangzhou, China
Actively Recruiting
Research Team
Q
Qian Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here